Purified anthocyanin supplementation reduces dyslipidemia, enhances antioxidant capacity, and prevents insulin resistance in diabetic patients.
J Nutr. 2015 Apr ;145(4):742-8. Epub 2015 Feb 4. PMID: 25833778
BACKGROUND: Oxidative stress plays an essential role in the pathogenesis of type 2 diabetes. Anthocyanin, a natural antioxidant, has been reported to reduce oxidative stress and to attenuate insulin resistance and diabetes in animal models; however, the translation of these observations to humans has not been fully tested.
OBJECTIVE: This study was designed to investigate the effects of purified anthocyanins on dyslipidemia, oxidative status, and insulin sensitivity in patients with type 2 diabetes.
METHODS: A total of 58 diabetic patients were given 160 mg of anthocyanins twice daily or placebo (n = 29/group) for 24 wk in a randomized, placebo-controlled, double-blind trial. Participants and investigators were masked to treatment allocation.
RESULTS: Anthocyanin supplementation significantly decreased serum LDL cholesterol (by 7.9%; P<0.05), triglycerides (by 23.0%; P<0.01), apolipoprotein (apo) B-48 (by 16.5%; P<0.05), and apo C-III (by 11.0%; P<0.01) and increased HDL cholesterol (by 19.4%; P<0.05) compared with placebo after the 24-wk intervention. In addition, patients in the anthocyanin group showed higher total radical-trapping antioxidant parameter and ferric ion reducing antioxidant power values than did patients in the placebo group (both P<0.05). Serum concentrations of 8-iso-prostaglandin F2α, 13-hydroxyoctadecadienoic acid, and carbonylated proteins in patients in the anthocyanin group were significantly less than in patients in the placebo group (23.4%, 25.8%; P<0.01 and 20%; P = 0.022, respectively). Furthermore, supplementation with anthocyanin lowered fasting plasma glucose (by 8.5%; P<0.05) and homeostasis model assessment for insulin resistance index (by 13%; P<0.05), and elevated serum adiponectin (by 23.4%; P<0.01) andβ-hydroxybutyrate (by 42.4%; P = 0.01) concentrations compared with placebo supplementation.
CONCLUSION: These findings demonstrate that anthocyanin supplementation exerts beneficial metabolic effects in subjects with type 2 diabetes by improving dyslipidemia, enhancing antioxidant capacity, and preventing insulin resistance. This trial was registered at www.clinicaltrials.gov as NCT02317211.